UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

Chinese medical journal, 2023-07, Vol.136 (14), p.1744-1746

2023

Volltextzugriff (PDF)

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Leukemia, 2020-02, Vol.34 (2), p.578-588

2020

Volltextzugriff (PDF)

Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

Haematologica (Roma), 2024-02, Vol.109 (2), p.591-603

2024

Volltextzugriff (PDF)

MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

Haematologica (Roma), 2024-05, Vol.109 (5), p.1619

2024

Volltextzugriff (PDF)

A Sole p.G391E Mutation in PML: : RARA Identified in Relapsed Acute Promyelocytic Leukemia

Turkish journal of haematology, 2024-09, Vol.41 (3), p.200-201

2024

Volltextzugriff (PDF)

The age-dependent changes in risk weights of the prognostic factors for multiple myeloma

Hematology (Luxembourg), 2023-12, Vol.28 (1), p.2258686-2258686

2023

Volltextzugriff (PDF)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e780045b-n/a

2023

Volltextzugriff (PDF)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

Cancer biology & medicine, 2023-01, Vol.20 (1), p.77-87

2023

Volltextzugriff (PDF)

The impact of response kinetics for multiple myeloma in the era of novel agents

Blood advances, 2019-10, Vol.3 (19), p.2895-2904

2019

Volltextzugriff (PDF)

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry

Blood, 2023-11, Vol.142 (Supplement 1), p.1920-1920

2023

Volltextzugriff (PDF)

P-174 Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in patients with new-diagnosed multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S131-S131

2023

Volltextzugriff (PDF)

P-327 Hyposecretory progression pattern indicates inferior survival of multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S219-S219

2023

Volltextzugriff (PDF)

Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7185-7186

2022

Volltextzugriff (PDF)

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.4371-4373

2022

Volltextzugriff (PDF)

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Blood, 2022-11, Vol.140 (Supplement 1), p.7255-7256

2022

Volltextzugriff (PDF)

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Blood, 2021-11, Vol.138 (Supplement 1), p.3765-3765

2021

Volltextzugriff (PDF)

P-340 Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S226-S227

2023

Volltextzugriff (PDF)

P-339 Longitudinal genetically detectable minimal residual disease by interphase fluorescence in situ hybridization confers a poor prognosis in multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S226-S226

2023

Volltextzugriff (PDF)

P-150 Autologous stem cell transplantation (ASCT) is still crucial for multiple myeloma (MM) patients with undetectable minimal residual disease after induction treatment

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S117-S118

2023

Volltextzugriff (PDF)

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Blood, 2022-11, Vol.140 (Supplement 1), p.10011-10012

2022

Volltextzugriff (PDF)

Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

Cancer, 2024-02, Vol.130 (3), p.421-432

2024

Volltextzugriff (PDF)

The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria

Leukemia & lymphoma, 2022-10, Vol.63 (12), p.2955-2964

2022

Volltextzugriff (PDF)

Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.1608-1608

2021

Volltextzugriff (PDF)

P-048: The value of autologous hematopoietic stem cell transplantation in multiple myeloma patients with MRD negative after early induction therapy

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S61-S62

2022

Volltextzugriff (PDF)

P-165: The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S125-S126

2022

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

A Sole p.G391E Mutation in PML: : RARA Identified in Relapsed Acute Promyelocytic Leukemia

The age-dependent changes in risk weights of the prognostic factors for multiple myeloma

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

The impact of response kinetics for multiple myeloma in the era of novel agents

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry

P-174 Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in patients with new-diagnosed multiple myeloma

P-327 Hyposecretory progression pattern indicates inferior survival of multiple myeloma

Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

P-340 Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

P-339 Longitudinal genetically detectable minimal residual disease by interphase fluorescence in situ hybridization confers a poor prognosis in multiple myeloma

P-150 Autologous stem cell transplantation (ASCT) is still crucial for multiple myeloma (MM) patients with undetectable minimal residual disease after induction treatment

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria

Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma

P-048: The value of autologous hematopoietic stem cell transplantation in multiple myeloma patients with MRD negative after early induction therapy

P-165: The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria

Suchergebnisse filtern